Literature DB >> 34845545

Laparoscopic cytoreductive surgery and HIPEC in LAMN with small volume of peritoneal disease: a valuable option of treatment for good patient-related experience measures (PREMs).

Caterina Cusumano1, Sébastien Carrere2, Alix Bouillin2, Stéphanie Nougaret3, Lakhdar Khellaf4, François Quénet2, Olivia Sgarbura5,6.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the best effective treatment for pseudomyxoma peritonei (PMP). In the last years, the advances in histopathology have stratified PMP lesions in different degrees of aggressivity suggesting the possibility of a tailored treatment. In a subset of patients with small volume peritoneal disease, laparoscopic CRS and HIPEC is feasible. The aim of this study is to analyze the results of laparoscopic CRS + HIPEC in a monocentric series of patients under patient-related experience measures (PREMs).
METHODS: All consecutive patients who underwent laparoscopic CRS-HIPEC with curative intent at Cancer Institute of Montpellier were retrieved from a prospectively maintained database and analyzed. Selection criteria for laparoscopic approach were low-grade PMP with pathological confirmation prior to CRS-HIPEC, age < 75 years, no extra-peritoneal disease, peritoneal cancer index (PCI) < 10, and a limited history of abdominal surgery. A PREMS interview was conducted before analysis with all the included patients. Outcomes of interest included postoperative morbidity, medium-term survival, and PREMs.
RESULTS: Fourteen patients were operated on for low-grade PMP with a laparoscopic approach at our institution. Conversions to laparotomy were necessary in three patients, and postoperative complications were observed in three patients (Clavien 3b in one patient). In-hospital postoperative median stay was 9.5 days. No death or recurrence was observed during the study period.
CONCLUSIONS: Laparoscopic CRS-HIPEC for LAMN in presence of small peritoneal disease is feasible in terms of postoperative morbidity and mortality. According to our PREMs questionnaire, patients' expectations were satisfied.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Laparoscopic CRS; Laparoscopic HIPEC; Mucinous peritoneal tumor; Pseudomyxoma peritonei

Mesh:

Year:  2021        PMID: 34845545     DOI: 10.1007/s00464-021-08816-0

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   3.453


  32 in total

1.  Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.

Authors:  G Passot; N Bakrin; A S Roux; D Vaudoyer; F-N Gilly; O Glehen; E Cotte
Journal:  Eur J Surg Oncol       Date:  2013-12-14       Impact factor: 4.424

2.  Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy by laparoscopy via a single-port approach for low-grade peritoneal malignancy.

Authors:  F Dumont; E Duchalais; A Aumont; E Thibaudeau
Journal:  Surg Endosc       Date:  2020-03-12       Impact factor: 4.584

3.  Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.

Authors:  Léonor Benhaim; Matthieu Faron; Maximiliano Gelli; Isabelle Sourrouille; Charles Honoré; Jean-Baptiste Delhorme; Dominique Elias; Diane Goere
Journal:  Surg Oncol       Date:  2019-04-03       Impact factor: 3.279

4.  Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Niharika Rajan Garach; Shigeki Kusamura; Marcello Guaglio; Valentina Bartolini; Marcello Deraco; Dario Baratti
Journal:  Eur J Surg Oncol       Date:  2020-08-25       Impact factor: 4.424

5.  Laparoscopic cytoreductive surgery and HIPEC: a comparative matched analysis.

Authors:  L Rodríguez-Ortiz; A Arjona-Sánchez; M Ibañez-Rubio; J Sánchez-Hidalgo; A Casado-Adam; S Rufián-Peña; J Briceño-Delgado
Journal:  Surg Endosc       Date:  2020-04-23       Impact factor: 4.584

Review 6.  Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis.

Authors:  P H Sugarbaker
Journal:  Semin Surg Oncol       Date:  1998 Apr-May

7.  Long-term results of laparoscopic cytoreductive surgery and HIPEC for the curative treatment of low-grade pseudomyxoma peritonei and multicystic mesothelioma.

Authors:  Frederic Mercier; Guedj Jeremie; Mohammad Alyami; Vaudoyer Delphine; Kepenekian Vahan; Rousset Pascal; Isaac Sylvie; Passot Guillaume; Glehen Olivier
Journal:  Surg Endosc       Date:  2019-12-02       Impact factor: 4.584

8.  The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry.

Authors:  L Villeneuve; G Passot; O Glehen; S Isaac; F Bibeau; P Rousset; F N Gilly
Journal:  Orphanet J Rare Dis       Date:  2017-02-17       Impact factor: 4.123

9.  Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for perforated low-grade appendiceal mucinous neoplasms.

Authors:  Haytham Abudeeb; Chelliah R Selvasekar; Sarah T O'Dwyer; Bipasha Chakrabarty; Lee Malcolmson; Andrew G Renehan; Malcolm S Wilson; Omer Aziz
Journal:  Surg Endosc       Date:  2020-01-28       Impact factor: 4.584

10.  The acceptance and applicability of a patient-reported experience measurement tool in oncological care: a descriptive feasibility study in northern Germany.

Authors:  Christiane Rudolph; Gitte Stentebjerg Petersen; Ron Pritzkuleit; Hans Storm; Alexander Katalinic
Journal:  BMC Health Serv Res       Date:  2019-11-01       Impact factor: 2.655

View more
  1 in total

Review 1.  Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies.

Authors:  Megan M Harper; Joseph Kim; Prakash K Pandalai
Journal:  J Clin Med       Date:  2022-05-18       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.